Full Text
PRS17 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY

Abstract

Authors

C Hampp TL Kauf A Saidi AG Winterstein

Back to Volume 12, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×